N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Phase 1 N=48 Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Phase 2 N=55 Antiplatelet Therapy in HIV
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
N/A N=334 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
PRU(Platelet Reactivity Unit) · APT(Antiplatelet Therapy) · HOTPR(High on Treat Platelet Reactivity)
Primary: Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects — 1; 1; 2 numbers of participants with MACE — p=0.002
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
N/A N=16 PACT (Platelet Activity After Clopidogrel Termination)
Blood Platelets · Clopidogrel
Primary: Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention. — 123.2; 126.7 mean fluorescence intensity (MFI)
N/A N=14 Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
Phase 2 N=40 Effects of Pioglitazone on Platelet Function
Diabetes · Platelet Function · Healthy
Primary: Percent Platelet Aggregation Induced by Arachidonic Acid — 80; 90; 60; 29 maximum percentage aggregation
Phase 2 N=27 Targeting Platelets in Chronic HIV Infection
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Phase 2 N=50 Clopidogrel Pharmacogenomics Project
Disease Susceptibility
Primary: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230 — 30; 18 Number of Patients with PRU>230 — p==0.02
Phase 4 N=24 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
Phase 2 N=12 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Phase 4 N=46 Platelet Transfusion During Neonatal Open Heart Surgery
Cardiac Disease · Cardiac Surgery · Cardiopulmonary Bypass
Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)
N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Phase 4 N=30 Platelet Inhibition in Patients With Systolic Heart Failure
Systolic Heart Failure
Primary: The Change in Platelet Aggregation Measured by the Accumetrics (VerifyNow P2Y12) Assay Between Baseline and Each Antiplatelet Medication — 66.4; 156.2 PRU (P2Y12…
Phase 3 N=1,351 Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Phase 4 N=5,276 Tailored Antiplatelet Therapy Following PCI
Coronary Artery Disease · Acute Coronary Syndrome · Stenosis
Primary: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. — 35; 54 Participants
Phase 4 N=60 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL
Phase 4 N=61 Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
Chronic Kidney Disease (CKD) · Type 2 Diabetes Mellitus (T2DM) · Coronary Artery Disease (CAD)
Primary: Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50% — 67.5; 67.2 PRI%
N/A N=27 The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
Coronary Artery Disease · Chest Pain
Primary: The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty — 32.8 Percent of platelets…
N/A N=117 Genetic Variation in Platelet Aggregation
Myocardial Infarction
Primary: LogEC50 Platelet Aggregation — 2.65; 2.62 nM
Phase 2 N=14 Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
Intracerebral Hemorrhage
Primary: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment — 68 seconds — p=0.014
Phase 3 N=40 The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
Platelet Dysfunction
Primary: Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx — 160.93 PRU
Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Phase 3 N=76 Chronic Kidney Disease (CKD) Platelet Study
Chronic Kidney Diseases · Heart Attack · Stroke, Ischemic
Primary: ADP Induced Platelet Aggregation — 0; 6; 1 ohms — p=0.002
Phase 4 N=14 Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 5; 24 PRU — p=<0.05
Phase 4 N=65 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Coronary Artery Disease
Primary: Platelet Reactivity — 36; 33 PRU
Phase 4 N=81 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Coronary Artery Disease
Primary: Platelet Reactivity Measured as PRU — 154.5; 23; 104 PRU